Publication: The Lancet
Tommy Nyberg, Prof Neil M Ferguson, Sophie G Nash, Harriet H Webster, Seth Flaxman, Nick Andrews, Wes Hinsley, Jamie Lopez Bernal, Meaghan Kall, Prof Samir Bhatt, Paula Blomquist, Asad Zaidi, Erik Volz, Nurin Abdul Aziz, Katie Harman, Prof Sebastian Funk, Sam Abbott, COVID-19 Genomics UK (COG-UK) consortium, Russell Hope, Andre Charlett, Meera Chand, Prof Azra C Ghani, Shaun R Seaman,
17 March 2022
The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort.View publication
Kamen A Tsvetanov, Lennart R B Spindler, Emmanuel A Stamatakis, Virginia FJ Newcombe, Victoria C Lupson, Doris A Chatfield, Anne E Manktelow, Joanne G Outtrim, Anne Elmer, Nathalie Kingston, John R Bradley, Edward T Bullmore, James B Rowe, David K Menon
02 February 2022
COVID-19 have seen multi-system effects that include neurological, vascular and neurovascular injury. Acute neurological sequelae are common, ranging from mild dizziness, headaches and anosmia to severe encephalitis, stroke and delirium. Researchers assessed the impact of COVID-19 on chronic cerebrovascular reactivity after hospitalisation.
Patients were recruited through the NIHR COVID-19 BioResource. Eligibility was based on admission to Addenbrookes Hospital with COVID-19 between 10th March 2020 and 31st July 2020, aged 18 years or older, survived the acute illness, and attended for a follow up visit, and no contradictions to MRI.
Bo Meng, Isabella A.T.M Ferreira, Adam Abdullahi, Steven A. Kemp, Niluka Goonawardane, Guido Papa, Saman Fatihi, Oscar J. Charles, Dami A. Collier, CITIID-NIHR BioResource COVID-19 Collaboration, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jinwook Choi, Joo Hyeon Lee, Petra Mlcochova, Leo James, Rainer Doffinger, Lipi Thukral, Kei Sato, View ORCID ProfileRavindra K. Gupta
21 December 2021
As the SARS-CoV-2 virus replicates and spreads, errors in its genetic code can lead to changes in the virus. Working in secure conditions, researchers created synthetic viruses – known as ‘pseudoviruses’ – that carried key mutations found in the Delta and Omicron strains. They used these to study the virus’s behaviour.
They tested the pseudoviruses against blood samples donated to the NIHR COVID-19 BioResource. The blood samples were from vaccinated individuals who had received two doses of either the AstraZeneca (ChAdOx-1) or Pfizer (BNT162b2) vaccines. Read the full story.View publication
Publication: Therapeutic Advances in Musculoskeletal Disease
Michael Barnes, Sarah Brockbank, Ian N Bruce, Coziana Ciurtin, Andrew P. Cop, Michael R. Ehrenstein, Paul Emery, Benjamin A. Fisher, John Isaacs, Ruth Matthews, Iain B. McInnes, Hayley Noble, Ayako Wakatsuki Pedersen, Costantino Pitzalis, Karim Raza, Anthony Rowe, Gemma Simpson, Dominic Stringer, Peter C. Taylor, Brian Tom, Yujie Zhong
Publication: Clinical Trials
Estée Török, Benjamin R Underwood, Mark Toshner, Claire Waddington, Emad Sidhom, Katherine Sharrocks, Rachel Bousfield, Charlotte Summers, Caroline Saunders, Zoe McIntyre, Helen Morris, Jo Piper, Gloria Calderon, Sarah Dennis, Tracy Assari, Anita Marguerie de Rotrou, Ashley Shaw, John Bradley, John O’Brien, Robert C Rintoul, Ian Smith, Ed Bullmore, Krishna Chatterjee
22 June 2021
Researchers describe their experience of rapidly setting up and delivering a novel COVID-19 vaccine trial, using clinical and research staff and facilities in three National Health Service Trusts in Cambridgeshire, United Kingdom.
Researchers encountered and overcame a number of challenges including differences in organisational structures, research facilities available, staff experience and skills, information technology and communications infrastructure, and research training and assessment procedures. These were overcome by setting up a project team that included key members from all three organisations that met at least daily by teleconference.View publication
Publication: Cell Reports
Bo Meng, Steven A. Kemp, Guido Papa, Rawlings Datir, Isabella A.T.M. Ferreira, Sara Marelli, William T. Harvey, Spyros Lytras, Ahmed Mohamed, Giulia Gallo, Nazia Thakur, Dami A. Collier, Petra Mlcochova
29 June 2021
One of the key mutations seen in the ‘Alpha variant’ of SARS-CoV-2 – the deletion of two amino acids, H69/V70 – enables the virus to overcome chinks in its armour as it evolves, say an international team of scientists.
SARS-CoV-2 is a coronavirus, so named because spike proteins on its surface give it the appearance of a crown (‘corona’). The spike proteins bind to ACE2, a protein receptor found on the surface of cells in our body. Both the spike protein and ACE2 are then cleaved, allowing genetic material from the virus to enter the host cell. The virus manipulates the host cell’s machinery to allow the virus to replicate and spread.
As SARS-CoV-2 divides and replicates, errors in its genetic makeup cause it to mutate. Some mutations make the virus more transmissible or more infectious, some help it evade the immune response, potentially making vaccines less effective, while others have little effect.
Towards the end of 2020, Cambridge scientists observed SARS-CoV-2 mutating in the case of an immunocompromised patient treated with convalescent plasma. In particular, they saw the emergence of a key mutation – the deletion of two amino acids, H69/V70, in the spike protein. This deletion was later found in B1.1.7, the variant that led to the UK being forced once again into strict lockdown in December (now referred to as the ‘Alpha variant’).
Researchers led by scientists at the University of Cambridge show that the deletion H69/V70 is present in more than 600,000 SARS-CoV-2 genome sequences worldwide, and has seen global expansion, particularly across much of Europe, Africa and Asia.
- Read the press release about this research.
Publication: Authorea (pre-print)
Mark Ferris, Rebecca Ferris, Chris Workman, Eoin O’Connor, David A Enoch, Emma Goldesgeyme, Natalie Quinnell, Parth Patel, Jo Wright, Geraldine Martell, Christine Moody, Ashley Shaw, Christopher J.R. Illingworth, Nicholas J. Matheson, Michael P. Weekes
24 June 2021
When Addenbrooke’s Hospital in Cambridge upgraded its face masks for staff working on COVID-19 wards to filtering face piece 3 (FFP3) respirators, it saw a dramatic fall – up to 100% – in hospital-acquired SARS-CoV-2 infections among these staff.
The findings are reported by a team at the University of Cambridge and Cambridge University Hospitals (CUH) NHS Foundation Trust. The research has not yet been peer-reviewed, but is being released early because of the urgent need to share information relating to the pandemic.View publication
Conde C Domínguez, T Gomes, LB Jarvis, C Xu, SK Howlett, DB Rainbow, O Suchanek, HW King, L Mamanova, K Polanski, N Huang, E Fasouli, KT Mahbubani, M Prete, L Campos, HS Mousa, EJ Needham, S Pritchard, T Li, R Elmentaite, J Park, DK Menon, OA Bayraktar, LK James, KB Meyer, MR Clatworthy, K Saeb-Parsy, JL Jones, SA Teichmann
28 April 2021
Despite their crucial role in health and disease, researchers knowledge of immune cells within human tissues, in contrast to those circulating in the blood, remains limited. Researchers surveyed the immune compartment of lymphoid and non-lymphoid tissues of six adult donors by single-cell RNA sequencing, including alpha beta T-cell receptor, gamma delta TCR and B-cell receptor variable regions.
To aid systematic cell type identification researchers developed CellTypist, a tool for automated and accurate cell type annotation. Using this approach combined with manual curation, researchers determined the tissue distribution of finely phenotyped immune cell types and cell states.View publication
Josephine M. Bryant, Karen P. Brown, Sophie Burbaud, Isobel Everall, Juan M. Belardinelli, Daniela Rodriguez-Rincon, Dorothy M. Grogono, Chelsea M. Peterson, Deepshikha Verma, Ieuan E. Evans, Christopher Ruis, Aaron Weimann, Divya Arora, Sony Malhotra, Bridget Bannerman, Charlotte Passemar, Kerra Templeton, Gordon MacGregor, Kasim Jiwa, Andrew J. Fisher, Tom L. Blundell, Diane J. Ordway, Mary Jackson, Julian Parkhill, R. Andres Floto
30 April 2021
Researchers have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients – showing that it can evolve rapidly within an individual during chronic infection. The researchers say their findings highlight the need to treat patients with Mycobacterium abscessus infection immediately, counter to current medical practice.View publication
Fotios Sampaziotis, Daniele Muraro, Olivia C. Tysoe, Stephen Sawiak, Timothy E. Beach, Edmund M. Godfrey, Sara S. Upponi, Teresa Brevini, Brandon T. Wesley, Jose Garcia-Bernardo, Krishnaa Mahbubani, Giovanni Canu, Richard Gieseck, Natalie L. Berntsen, Victoria L. Mulcahy, Keziah Crick, Corrina Fear, Sharayne Robinson, Lisa Swift, Laure Gambardella, Johannes Bargehr, Daniel Ortmann, Stephanie E. Brown, Anna Osnato, Michael P. Murphy, Gareth Corbett, William T. H. Gelson, George F. Mells, Peter Humphreys, Susan E. Davies, Irum Amin, Paul Gibbs, Sanjay Sinha, Sarah A. Teichmann, Andrew J. Butler, Teik Choon, Espen Melum, Christopher J. E. Watson, Kourosh Saeb-Parsy, Ludovic Vallier
18 February 2021
Researchers in Cambridge have found a way to grow ‘mini bile ducts’ in a lab-setting to repair damaged livers. This new technique could potentially help treat patients whose own livers are not functioning correctly.
Using a recently developed ‘perfusion system’, they were able to transplant biliary cells grown in the lab known as cholangiocytes organoids into damaged human livers to repair them.
This is the first time that a procedure of this kind has been used on human donor organs. It could also increase the number of livers that are considered suitable for organ transplantation and ultimately save more lives.
Read the full storyView publication
Publication: Cell Stem Cell
Jeonghwan Youk, Taewoo Kim, Kelly V.Evans, Young-IlJeong, Yongsuk Hur, Seon Pyo Hong, Je Hyoung Kim, Kijong Yi, Su Yeon Kim, Kwon JoongNa, Thomas Bleazard, Ho Min Kim, Mick Fellows, Krishnaa T. Mahbubani, Kourosh Saeb-Parsy, Seon Young Kim, Young Tae Kim, Gou YoungKoh, Joo-Hyeon Lee
21 October 2020
To better understand how SARS-CoV-2 infects the lungs and causes disease, a team of scientists from the UK and South Korea turned to organoids – ‘mini-organs’ grown in three dimensions to mimic the behaviour of tissue and organs.
The team used tissue donated to tissue banks at the Royal Papworth Hospital NHS Foundation Trust and Addenbrooke’s Hospital, Cambridge University NHS Foundations Trust, UK, and Seoul National University Hospital to extract a type of lung cell known as human lung alveolar type 2 cells. By reprogramming these cells back to their earlier ‘stem cell’ stage, they were able to grow self-organising alveolar-like 3D structures that mimic the behaviour of key lung tissue.
Read the full press releaseView publication
Publication: Clinical Transplantation
John O. O. Ayorinde, Mazin Hamed, Mingzheng Aaron Goh, Dominic M. Summers, Anna Dare, Yining Chen, Kourosh Saeb‐Parsy
20 January 2020
This research recorded donor and recipient data of kidney transplants and matched them with clinical outcomes, helping to build the Cambridge Kidney Assessment Tool (CKAT).
CKAT will assist surgeons to define macroscopic features of donor kidneys to help them better predict clinical outcome and help reduce unecessary discarding of donor kidneys offered for transplantion.View publication
Publication: Nature Metabolism
Jack L. Martin, Ana S. H. Costa, Anja V. Gruszczyk, Timothy E. Beach, Fay M. Allen, Hiran A. Prag, Elizabeth C. Hinchy, Krishnaa Mahbubani, Mazin Hamed, Laura Tronci, Efterpi Nikitopoulou, Andrew M. James, Thomas Krieg, Alan J. Robinson, Margaret M. Huang, Stuart T. Caldwell, Angela Logan, Laura Pala, Richard C. Hartley, Christian Frezza, Kourosh Saeb-Parsy, Michael P. Murphy
30 September 2019
During retrieval of kidneys for transplant, there is inevitably a period of time when the organ is without blood flow but still warm (warm ischaemia). A human kidney cannot sustain this for long. During warm ischaemia, a metabolite called succinate builds up. When blood flow is restored, then counter-intuitively, the kidney tissue is damaged with the arrival of oxygenated blood. A drug was tested that ameliorates this damage. This research shows how the function and life span of a transplanted organ can be improved.View publication
Publication: Nature Medicine
Felipe A. Vieira Braga, Gozde Kar, Marijn Berg, Orestes A. Carpaij, Krzysztof Polanski, Lukas M. Simon, Sharon Brouwer, Tomás Gomes, Laura Hesse, Jian Jiang, Eirini S. Fasouli, Mirjana Efremova, Roser Vento-Tormo, Carlos Talavera-López, Marnix R. Jonker, Karen Affleck, Subarna Palit, Paulina M. Strzelecka, Helen V. Firth, Krishnaa T. Mahbubani, Ana Cvejic, Kerstin B. Meyer, Kourosh Saeb-Parsy, Marjan Luinge, Corry-Anke Brandsma, Wim Timens, Ilias Angelidis, Maximilian Strunz, Gerard H. Koppelman, Antoon J. van Oosterhout, Herbert B. Schiller, Fabian J. Theis, Maarten van den Berge, Martijn C. Nawijn, Sarah A. Teichmann
17 June 2019
This research carried out a survey of structural and immune cells in the airways of healthy and asthmatic lungs and identified a novel set of T cells resident in asmatic airways. There is altered communication between immune and structural cells in asthmatic airways and these changes underlie the inflammation in these airways.View publication
Publication: Journal of Autoimmunity
M. Saeed Qureshi, Jawaher Alsughayyir, Manu Chhabra, Jason M. Ali, Martin J. Goddard, Christopher A. Devine, Thomas M. Conlon, Michelle A. Linterman, Reza Motallebzadeh, Gavin J.Pettigrew
7 December 2018
The development of humoral autoimmunity following organ transplantation is increasingly recognised, but of uncertain significance. We examine whether autoimmunity contributes independently to allograft rejection.View publication
Publication: Frontiers in Immunology
Jacqueline H. Y. Siu, Veena Surendrakumar, James A. Richards and Gavin J. Pettigrew
5 November 2018
Transplantation is unusual in that T cells can recognize alloantigen by at least two distinct pathways: as intact MHC alloantigen on the surface of donor cells via the direct pathway; and as self-restricted processed alloantigen via the indirect pathway. Direct pathway responses are viewed as strong but short-lived and hence responsible for acute rejection, whereas indirect pathway responses are typically thought to be much longer lasting and mediate the progression of chronic rejection. However, this is based on surprisingly scant experimental evidence, and the recent demonstration that MHC alloantigen can be re-presented intact on recipient dendritic cells—the semi-direct pathway—suggests that the conventional view may be an oversimplification.View publication
Publication: Frontiers in Immunology
Jawaher Alsughayyir, Manu Chhabra, M. Saeed Qureshi, Mekhola Mallik, Jason M. Ali, Ivonne Gamper, Ellen L. Moseley, Sarah Peacock, Vasilis Kosmoliaptsis, Martin J. Goddard, Michelle A. Linterman, Reza Motallebzadeh, Gavin J. Pettigrew
22 January 2019
Humoral alloimmunity is now recognized as a major determinant of transplant outcome. MHC glycoprotein is considered a typical T-dependent antigen, but the nature of the T cell alloresponse that underpins alloantibody generation remains poorly understood. This paper examines how the relative frequencies of alloantigen-specific B cells and helper CD4 T cells influence the humoral alloimmune response and how this relates to antibody-mediated rejection (AMR).View publication
Publication: Frontiers in Immunology
Manu Chhabra, Jawaher Alsughayyir, M. Saeed Qureshi, Mekhola Mallik, Jason M. Ali, Ivonne Gamper, Ellen L. Moseley, Sarah Peacock, Vasilis Kosmoliaptsis, Martin J. Goddard, Michelle A. Linterman, Reza Motallebzadeh and Gavin J. Pettigrew
23 January 2019
Different profiles of alloantibody responses are observed in the clinic, with those that persist, often despite targeted treatment, associated with poorer long-term transplant outcomes. Although such responses would suggest an underlying germinal center (GC) response, the relationship to cellular events within the allospecific B cell population is unclear. Here we examine the contribution of germinal center (GC) humoral alloimmunity to chronic antibody mediated rejection (AMR)…
This work is composed of two parts, of which this is Part II. Please read also Part I: Alsughayyir et al., 2019.View publication
Publication: BMJ Open
John OO Ayorinde, Dominic M Summers, Laura Pankhurst, Emma Laing, Alison J Deary, Karla Hemming, Edward CF Wilson, Victoria Bardsley, Desley A Neil, Gavin J Pettigrew
17 January 2019
Most potential kidney transplant donors in the UK are aged over 60 years, yet increasing donor age is associated with poorer graft survival and function. Urgent preimplantation kidney biopsy can identify chronic injury, and may aid selection of better ‘quality’ kidneys from this group. However, the impact of biopsy on transplant numbers remains unproven. The PreImplantation Trial of Histopathology In renal Allografts (PITHIA) study will assess whether the introduction of a national, 24 hours, digital histopathology service increases the number, and improves outcomes, of kidneys transplanted in the UK from older deceased donors.View publication
Publication: Journal of Hepatology
Rhiannon Taylor, Elisa Allen, James A. Richards, Mingzheng A. Goh, James Neuberger, David Collett, Gavin J. Pettigrew, Liver Advisory Group to NHS Blood and Transplant
11 January 2019
This study looks at patients who require a liver transplant to save their lives; this liver can be donated by a person who has died either after their heart has stopped (donation after cardiac death – DCD) or after the brain has been injured and can no longer support life (donation after brainstem death – DCB). We know that livers donated after brainstem death function better than those after cardiac death, but there are not enough of these livers for everyone, so we wished to help patients decide whether it was better for them to accept an early offer of a DCD liver than waiting longer to receive a “better” liver from a DBD donor. We found that patients were more likely to survive if they accepted the offer of a liver transplant as soon as possible (DCD or DBD), especially if their liver disease was very severe.View publication
Publication: American Journal of Transplantation
Ines G. Harper, Olivera Gjorgjimajkoska, Jacqueline H. Y. Siu, Jasvir Parmar, Arend Mulder, Frans H. J. Claas, Sarah A. Hosgood, Michael L. Nicholson, Reza Motallebzadeh, Gavin J. Pettigrew
12 December 2018
Tissue resident lymphocytes are present within many organs, and are presumably transferred at transplantation, but their impact on host immunity is unclear. Here, we examine whether transferred donor natural regulatory CD4 T cells (nT‐regs) inhibit host alloimmunity and prolong allograft survival.View publication
Ng SS, Saeb-Parsy K, Blackford SJI, Segal JM, Serra MP, Horcas-Lopez M, No DY, Mastoridis S, Jassem W, Frank CW, Cho NJ, Nakauchi H, Glenn JS, Rashid ST. Biomaterials.
November 2018View publication
Publication: Scientific Reports
Wang J, Ferreira R, Lu W, Farrow S, Downes K, Jermutus L, et al.
13 August 2018View publication
Publication: The Lancet
Gemma D Banham, MRCP(UK), Shaun M Flint, FRACP, Nicholas Torpey, FRCP, Paul A Lyons, PhD, Don N Shanahan, MSc, Adele Gibson, BSc, Prof Christopher J E Watson, FRCS, Ann-Marie O’Sullivan, MRes, Joseph A Chadwick, Katie E Foster, PhD, Rachel B Jones, FRCP, Luke R Devey, MRCSEd, Anna Richards, MRCP(UK), Prof Lars-Peter Erwig, MD, Prof Caroline O Savage,FMedSci, Prof Kenneth G C Smith, FMedSci, Robert B Henderson, PhD, Menna R Clatworthy, FRCP†
14 June 2018
Transplantation is the best form of treatment for most patients with end-stage renal failure, but long-term graft survival is limited by the development of antibodies against the graft. There is therefore a major unmet need to find immunosuppressants that target humoral alloimmunity.
Researchers investigated the use of Belimumab, a monoclonal antibody that binds the B cell pro-survival cytokine BAFF, in kidney transplant recipients.
The study found that the use of belimumab was not associated with any excess risk of infection, and led to a reduction in antibody-producing plasmablasts, activated memory B cells, new IgG antibody formation and in non-HLA IgG antibodies associated with poor graft outcomes. Remarkably, belimumab treatment spared regulatory B cells – a cell type associated with transplant tolerance, with an increase in IL10-producing B cells observed.View publication
Publication: Pediatric Nephrology
Martin JL, Gruszczyk AV, Beach TE, Murphy MP, Saeb-Parsy K.
2 June 2018View publication
Publication: Journal of the American Heart Association
Kohlhauer M, Dawkins S, Costa ASH, Lee R, Young T, Pell VR, Choudhury RP, Banning AP, Kharbanda RK; Oxford Acute Myocardial Infarction (OxAMI) Study, Saeb-Parsy K, Murphy MP, Frezza C, Krieg T, Channon KM.
6 April 2018View publication
Publication: American Journal of Transplantation
Watson CJE, Kosmoliaptsis V, Pley C, Randle L, Fear C, Crick K, et al.
8 February 2018View publication
Linda M. O’Keeffe, PhD; Anna Ramond, DPharm; Clare Oliver-Williams, PhD; Peter Willeit, MD; Ellie Paige, PhD; Patrick Trotter, MBChB; Jonathan Evans, MBChB; Jonas Wadström, MD; Michael Nicholson, MD; Dave Collett, PhD; Emanuele Di Angelantonio, MD
30 January 2018
Living kidney donors are not at increased risk for some health outcomes previously of concern, but do seem at risk for worse blood pressure and kidney function than nondonors. In addition, female donors seem to be at increased risk for preeclampsia.
A team lead by researchers reviewed 52 published studies comprising more than 100,000 living kidney donors and more than 110,000 nondonors to assess the mid- and long-term health risks associated with living kidney donation in adults.
The data showed that kidney donors had higher diastolic blood pressure, poorer renal function, and higher risk for ESRD than nondonors. Female donors had an almost two-fold higher risk than nondonors for pregnancy-related complications, such as preeclampsia.
There was no evidence that living kidney donors had higher risk for mortality, cardiovascular disease, or type 2 diabetes, or reduced quality of life.View publication
Norah M. E. Fogarty, Afshan McCarthy, Kirsten E. Snijders, Benjamin E. Powell, Nada Kubikova, Paul Blakeley, Rebecca Lea, Kay Elder, Sissy E. Wamaitha, Daesik Kim, Valdone Maciulyte, Jens Kleinjung, Jin-Soo Kim, Dagan Wells, Ludovic Vallier, Alessandro Bertero10, James M. A. Turner & Kathy K. Niakan
20 September 2017View publication
Publication: Clin Transplant
Mah TJ, Mallon DH, Brewster O, Saeb-Parsy K, Butler AJ, Bradley JA, Kosmoliaptsis V.
23 January 2017View publication
Publication: Transpl Int
Amin I, Butler AJ, Defries G, Russell NK, Harper SJ, Jah A, Saeb-Parsy K, Pettigrew GJ, Watson CJ.
21 January 2017View publication
Publication: Diabetes Obes Metab
El-Khairi R, Vallier L.
12 September 2016View publication
Publication: Curr Opin Organ Transplant
Inaba A, Clatworthy MR.
August 2016View publication
Mirshekar-Syahkal B, Summers D, Bradbury LL, Aly M, Bardsley V, Berry M, Norris JM, Torpey N, Clatworthy MR, Bradley JA, Pettigrew GJ
18 July 2016View publication
Publication: Cell Reports
Harper IG, Ali JM, Harper SJ, Wlodek E, Alsughayyir J, Negus MC, Qureshi MS, Motalleb-Zadeh R, Saeb-Parsy K, Bolton EM, Bradley JA, Clatworthy MR, Conlon TM, Pettigrew GJ.
28 April 2016View publication
Publication: Am J Transplant
Kosmoliaptsis V, Mallon DH, Chen Y, Bolton EM, Bradley JA, Taylor CJ.
11 January 2016View publication
Publication: Am J Transplant
Watson CJ, Kosmoliaptsis V, Randle LV, Russell NK, Griffiths WJ, Davies S, Mergental H, Butler AJ.
22 September 2015View publication